# US 2021/0332104 A1 · Therapeutic peptides and methods for treating autoimmune related disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0332104 A1
- Document ID: US20210332104A1
- Status: Published application
- Kind: A1
- Application number: 17/365,881
- Filed: 2021-07-01
- Published: 2021-10-28
- Earliest claimed: 2018-05-10
- Assignees: Op-T LLC
- Applicants: Op-T LLC
- Inventors: David H. Wagner Jr.; Martin G. Yussman; Charles W. Henry
- Web page: https://patentgrep.com/patent/US20210332104A1

## CPC

- C07K 14/70575: {NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154 (NGF C07K14/48, TNF C07K14/525)}
- A61K 38/191: {Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta}
- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 38/1774: {Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)}
- A61K 40/4215: {Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Methods and materials for preventing and modulating atherosclerosis. In particular, small peptides that are capable of interacting with CD40, thereby interfering with the ability of CD40 to interact with CD154, which impacts inflammation and atherosclerosis. The use of such peptides in reducing atherosclerosis, and in particular, the autoimmune inflammatory response that may be a driving factor thereof. The use of such short peptides to lower LDL cholesterol. Methods and materials for detecting T-cells that express CD40 (Th40 cells). Methods and materials for preventing, modulating, reducing and/or reversing type 2 diabetes and auto-inflammatory disease. In particular, small peptides that are capable of interacting with CD40, thereby interfering with the ability of CD40 to interact with CD154, which impacts inflammation and type 2 diabetes. The use of such peptides in reducing type 2 diabetes, and in particular, the autoimmune inflammatory response that may be a driving factor thereof. The use of such short peptides to lower IL2, INFγ, and IL17a. The use of such peptides to increase glucose transport protein (GLUT4). Methods and materials for detecting T-cells that express CD40 (Th40 cells).

## Claims

### Claim at position 1

52-90. (canceled)

### Claim 91

A method for preventing, modulating, reducing, treating, and/or reversing type 2 diabetes in a subject, the method comprising administering to the subject a therapeutically effective amount of a peptide of 6 amino acids in length and having an amino acid sequence of SEQ ID NO: 28 or 29.

### Claim 92 (depends on 91)

The method of claim 91, wherein the peptide binds to a CD40 protein in the subject.

### Claim 93 (depends on 92)

The method of claim 92, wherein the peptide binds to the CD40 protein with a Kd of greater than 10-6.

### Claim 94 (depends on 91)

The method of claim 91, wherein the peptide inhibits the binding of CD40 to CD154 in the subject.

### Claim 95 (depends on 91)

The method of claim 91, wherein administration of the peptide inhibits expansion of Th40 cells in the subject.

### Claim 96 (depends on 91)

The method of claim 91, wherein administration of the peptide reduces the number of Th40 cells in the subject.

### Claim 97 (depends on 91)

The method of claim 91, wherein administration of the peptide alters the cytokine expression profile in the subject.

### Claim 98 (depends on 91)

The method of claim 91, wherein administration of the peptide modulates glucose transport protein 4 (GLUT 4) in the subject.

### Claim 99 (depends on 91)

The method of claim 91, wherein administration of the peptide modulates expression and/or activity of IL-2 or IL-17A in the subject.

### Claim 100 (depends on 91)

The method of claim 91, wherein administration of the peptide modulates expression and/or activity of IFNγ in the subject.

### Claim 101 (depends on 91)

The method of claim 91, wherein the peptide binds to multiple bone marrow derived cell types that express CD40 of approximately 45 kDa.

### Claim 102 (depends on 101)

The method of claim 101, wherein the bone marrow derived cell types that express CD40 of approximately 45 kDa comprise splenic CD4hi cells, CD8 cells, and other antigen presenting cells.

### Claim 103 (depends on 91)

The method of claim 91, wherein the peptide is administered in an amount sufficient to reduce or inhibit interleukin-2 signaling in the subject.

### Claim 104 (depends on 91)

The method of claim 91, wherein the peptide is administered in an amount sufficient to reduce or inhibit interleukin 17 (IL-17) signaling.

### Claim 105 (depends on 91)

The method of claim 91, wherein the peptide has an amino acid sequence of SEQ ID NO: 28.

### Claim 106 (depends on 91)

The method of claim 91, wherein the peptide has an amino acid sequence of SEQ ID NO: 29.

### Claim 107 (depends on 91)

The method of claim 91, wherein the subject is human.

### Claim 108

A method for preventing, modulating, reducing, treating, and/or reversing glucose intolerance and/or insulin insensitivity in a subject, the method comprising administering to the subject a therapeutically effective amount of a peptide of 6 amino acids in length and having an amino acid sequence of SEQ ID NO: 28 or 29.

### Claim 109 (depends on 108)

The method of claim 108, wherein administration of the peptide reduces the number of Th40 cells in the subject.

### Claim 110

A method for preventing, modulating, reducing, treating, and/or reversing atherosclerosis in a subject, the method comprising administering to the subject a therapeutically effective amount of a peptide of 6 amino acids in length and having an amino acid sequence of SEQ ID NO: 28 or 29.

### Claim 111 (depends on 110)

The method of claim 110, wherein administration of the peptide reduces the number of Th40 cells in the subject.

### Claim 112

A pharmaceutical composition comprising a peptide of six amino acids in length and having an amino acid sequence of SEQ ID NO: 28 or 29.